Array anti-cancer drug falling short

BOULDER – Results of a study on the effectiveness of an anti-cancer drug developed by Array BioPharma Inc. demonstrated an increase in survival rates when combined with another drug, but the results did not reach statistical significance, according to the Boulder-based bioscience company.

The Phase 2 study, conducted by AstraZeneca, demonstrated an increase in survival among 87 patients taking Array’s selumetinib in combination with docetaxel versus docetaxel alone. The patients were prospectively selected with KRAS-mutant, locally advanced or metastatic nonsmall-cell lung cancer.

AstraZeneca is also completing a Phase 2 trial with selumetinib in combination with dacarbazine compared with dacarbazine alone as first-line treatment of patients with melanoma whose tumors harbor BRAF mutations.

SPONSORED CONTENT

How Platte River is proactively managing its clean energy transition costs

Learn more about how Platte River Power Authority is proactively managing its clean energy transition costs across the region.

There are more than 45 on-going or completed Phase 1 or 2 trials with selumetinib.